CBP-307 is an orally-active small molecule modulator of S1P1, a G-protein coupled receptor on the surface of certain populations of T cells. CBP-307 works by causing internalization of S1P1, known to be critical for T cell trafficking into inflamed tissues. This drug candidate is designed to avoid the side effects on cardiovascular, lung and liver functions that are known for a marketed, first-generation drug targeting the same receptor. Based our Phase 1a and Phase 1b clinical data, we believe this compound has the potential to be far superior to the first-generation compound and has advantages over other second-generation compounds now in various stages of development. 

Phase I studies of CBP-307 were completed in Australia. The drug exhibited potent T cell modulation activity while it was found to be safe and well tolerated. IND application in China was approved for clinical trials on 5 indications (i.e. Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis and Multiple Sclerosis) by CFDA in January 2017. Phase II trials in inflammatory bowel disease (IBD) will commence in H1 2018.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower